On February 17, 2026 BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reported that the Company will participate in fireside chats at four upcoming investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET;
Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET;
Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and
Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET

Live webcasts of these events can be accessed from the investors section of the Company’s website at View Source Archived replays will be available on the Company’s website.

(Press release, BeOne Medicines, FEB 17, 2026, View Source [SID1234662728])

On February 17, 2026 Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, reported it will present recent company progress including the ongoing Phase 1 clinical trial uTREAT in glioblastoma, at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, 2026, at 11:50 a.m. Eastern Time / 5:50 p.m. CET in Boston.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after the webcast.

During the conference, Curasight management will also hold 1:1 meetings with investors and other industry stakeholders.

The TD Cowen conference is a major investor conference where public and private healthcare companies meet with institutional investors, and large pharma via scheduled 1×1 meetings and presentations combined with fireside chats and innovative panel discussions.

(Press release, Curasight, FEB 17, 2026, View Source [SID1234662729])

On February 16, 2026 Jecho Laboratories, Inc. reported that the company has been selected for a podium presentation at the upcoming BIO Investment & Growth Summit 2026, a leading international forum for biotechnology and life science emerging companies. Hosted by the Biotechnology Innovation Organization (BIO), the Summit brings together biotechnology companies, investors, bankers, and strategic partners to highlight investment trends, dealmaking and commercialization, regulatory policies, and capital formation opportunities across the industry.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BIO Investment & Growth Summit will be held March 2-3, 2026 in Miami Beach, FL.

Jecho will be presenting recent company breakthroughs on Monday, March 2, 2026 at 4:30 p.m. in the ERC Ballroom of the Eden Roc Miami.

(Press release, Jecho Laboratories, FEB 16, 2026, View Source [SID1234662688])

On February 16, 2026 Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapy for the treatment of solid tumours, reported that it will present interim clinical data at the 2026 European Association of Urology (EAU) Annual Congress, taking place in London, UK, 13th – 16th March, and the 2026 American Urological Association (AUA) Annual Meeting, taking place in Washington, DC, US, 15th – 18th May. Both conferences have accepted Prokarium’s work for oral presentation, which reflects the growing recognition of the high potential of its bacterial immunotherapy platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At EAU and AUA, Prokarium will share important emerging findings from the company’s ongoing Phase 1/1b clinical trial, PARADIGM-1 (NCT06181266), assessing the safety, pharmacology, and preliminary clinical efficacy of ZH9 treatment in patients with non-muscle invasive bladder cancer (NMIBC).

"We are delighted that our work has been selected for oral presentations at two of the most prestigious global urology meetings, in particular a podium presentation at the AUA" said Ibs Mahmood, CEO. "These invitations underscore the growing interest in our transformational treatment aiming to shift the standard of care for patients with bladder cancer, and I think the community is going to be very excited when they hear the results"

The 41st European Association of Urology Annual Congress Information:

Presentation Title: PARADIGM 1 – A multi-center Phase 1 study evaluating the safety and clinical effect of a novel microbial immunotherapeutic (ZH9) in patients with relapsed NMIBC – A first interim review (Abstract ID: A0089)
Session Title: High-risk NMIBC: Evolving BCG–immunotherapy strategies and technical advances in TURB (Abstract Session 05)
Session Date and Time: Friday 13th March, 16:20 – 16:56
The American Urology Association Annual Meeting information:

Presentation title: PARADIGM 1 – A multi-center Phase 1 study evaluating the safety and clinical effect of a novel microbial immunotherapeutic (ZH9) in patients with relapsed NMIBC – A first interim review (Abstract ID: 26-1116)
Session Title: Podium Presentation PD09, Bladder Cancer: Non-Invasive III
Session Date and Time: Saturday 16th May, 07:00 – 09:00

(Press release, Prokarium, FEB 16, 2026, View Source [SID1234662689])

On February 16, 2026 Delphi reported that new data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) from the NRG/NSABP B-42 trial demonstrated that the Endocrine Activity Index (EAI) identifies postmenopausal women with hormone receptor–positive (HR+), HER2-negative breast cancer who may derive meaningful benefit from extended endocrine therapy. The findings were presented by Eleftherios P. Mamounas, MD, AdventHealth Cancer Institute, Orlando, FL, in a general session on behalf of the NRG Oncology/NSABP investigators, under the title: "Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Extended endocrine therapy beyond five years can reduce the risk of late breast cancer recurrence, but benefits must be weighed against cumulative side effects. Clinicians have limited options to identify which patients are most likely to benefit from prolonged treatment.

The NRG/NSABP B-42 trial evaluated extended letrozole therapy (ELT) versus placebo in postmenopausal women with HR+ breast cancer who had already completed five years of adjuvant endocrine therapy and demonstrated a small (3.3%) but significant benefit of ELT in this patient population. This new analysis examined whether the EAI test, a genomic signature that measures endocrine activity, could predict benefit from ELT.

Patients with high endocrine activity (EAI ≥ 1.50) experienced a statistically significant and clinically meaningful benefit from ELT, with a 10-year absolute BCFI benefit of 7.1%. Patients with lower EAI values (<1.50) did not experience a statistically significant benefit from extended therapy. This benefit was observed across nodal subgroups and was most pronounced in node-positive patients with high EAI scores, demonstrating a 10.5% absolute reduction in BCFI events compared to placebo. Treated as a continuous variable, higher EAI values were associated with a progressively greater relative benefit from ELT.

"EAI is the only test that can provide insight into how active the estrogen/progesterone pathway of a breast cancer tumor is," said Delphi Diagnostics Chief Medical Officer, Federico A. Monzon. "Data from the B-42 study supports the hypothesis that longer durations of endocrine therapy are most effective for patients whose cancers are highly endocrine-sensitive. This data continues to establish EAI as an important signature that can provide patient-specific insights to support treatment decisions for breast cancer patients."

About EAI
Delphi Diagnostics’ Endocrine Activity Index (EAI) test can provide actionable information for prognosis and prediction of dose-intense taxane-based chemotherapy benefit in stage II-III, HR+ HER2- breast cancer. The EAI measures endocrine activity in a breast tumor and for prognostic use, the Index Score is adjusted for baseline prognosis using molecular subtype genes (RNA4) and clinical factors such as tumor size and regional lymph node involvement. The EAI test has been shown in various studies to be a consistent prognostic indicator for long-term outcomes in stage II-III breast cancer patients, to be independent of other prognostic tests, as well as to be predictive for response to dose-dense chemotherapy.

(Press release, Delphi, FEB 16, 2026, View Source [SID1234662690])